Biotech

All Articles

Ascendis' dwarfism medicine favorites in phase 3, threatens BioMarin

.Ascendis Pharma has emerged as a possible danger to BioMarin's Voxzogo, reporting phase 3 growth co...

Despite ph. 3 miss, Alkeus finds road ahead of time for eye health condition possession

.Though Alkeus Pharmaceuticals' oral eye health condition resource fell short to significantly lesse...

Kairos goes social with $6M IPO to cash tests of cancer drug

.Along with a triad of biotechs striking the Nasdaq on Friday, it was easy to miss out on a smaller-...

Vaccine and Keytruda combination effective in squamous tissue cancer

.Invulnerable checkpoint preventions are actually the superheroes of cancer cells treatment. Medicat...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of considerable leadership hirings, shootings an...

Regeneron's Opdualag competitor shows 57% feedback fee

.Regeneron is back with lasting follow-up for its LAG-3 prevention as well as PD-1 prevention combin...

AstraZeneca articles records on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early look at the performance of its own in-house antibody-drug conju...

iTeos- GSK's TIGIT celebrity presents relevant enhancement

.After revealing a stage 3 launch based on positive midstage results, iTeos and also GSK are lastly ...

More joint FDA can increase rare illness R&ampD: report

.The FDA ought to be actually even more available as well as collaborative to discharge a surge in c...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It's an abnormally hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as Bicar...